Adjuvant therapy after surgery for stomach cancer that responded fully to initial treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies which follow-up treatment is better for people with stomach or gastroesophageal junction cancer who had complete response to chemotherapy and immunotherapy before surgery, and whose tumor was completely removed. The goal is to reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stomach or gastroesophageal junction cancer that is adenocarcinoma (the most common type).
- Your cancer does not have HER2 overexpression or amplification.
- You received at least 3-4 cycles of chemotherapy plus immunotherapy before surgery.
- After surgery, pathology showed no cancer cells (complete response, pCR).
- Your doctor thinks you need further treatment after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to chemotherapy after surgery for stomach or gastroesophageal junction cancer helps prevent the cancer from coming back. It is for people whose cancer is HER2-negative and who have had the tumor completely removed.
This study compares two treatment plans after surgery for stomach cancer: chemotherapy alone versus chemotherapy plus immunotherapy (a treatment that helps your immune system fight cancer). The goal is to see which plan is better at preventing cancer from returning.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
This trial tests a new treatment plan after surgery for stomach cancer that shows certain markers, to reduce the chance of the cancer coming back. It includes drugs that help your immune system fight cancer.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.